Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Kevin J. Harrington(Royal Marsden NHS Foundation Trust), J. Guigay(Centre Antoine Lacassagne), Kim Cocks(University of Leeds), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Naomi Kiyota(Kobe University Hospital), Nabil F. Saba(Emory University), L Morrissey(Adelphi Laboratory Center), Lisa Licitra(University of Milan), James W. Shaw(University of Illinois Chicago), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Manish Monga(Institut Gustave Roussy), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Robert L. Ferris(University of Pittsburgh), Fiona Taylor(Adelphi Laboratory Center), Caroline Even(Institut Gustave Roussy), Viktor Grünwald(Deutsche Schmerzgesellschaft), Michael DeRosa(Adelphi Laboratory Center), Stefan Kasper(Essen University Hospital)
Cited by 431
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Statins for the primary prevention of cardiovascular disease
|Cochrane Database of Systematic Reviews|2013|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k